Longboard Pharmaceuticals (LBPH) Stock Forecast, Price Target & Predictions
LBPH Stock Forecast
Longboard Pharmaceuticals stock forecast is as follows: an average price target of $70.00 (represents a 16.71% upside from LBPH’s last price of $59.98) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.
LBPH Price Target
The average price target for Longboard Pharmaceuticals (LBPH) is $70.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $90.00 to $60.00. This represents a potential 16.71% upside from LBPH's last price of $59.98.
LBPH Analyst Ratings
According to 6 Wall Street analysts, Longboard Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for LBPH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (33.33%), 4 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Longboard Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | Kalpit Patel | B.Riley Financial | $60.00 | $58.83 | 2.00% | 0.03% |
| Sep 18, 2024 | Patrick Trucchio | H.C. Wainwright | $80.00 | $27.58 | 190.07% | 33.38% |
| Sep 10, 2024 | Joon Lee | Truist Financial | $60.00 | $34.51 | 73.86% | 0.03% |
| Sep 06, 2024 | Joel Beatty | Robert W. Baird | $60.00 | $33.89 | 77.04% | 0.03% |
| Jul 01, 2024 | Josh Schimmer | Cantor Fitzgerald | $90.00 | $28.76 | 212.93% | 50.05% |
| Jun 10, 2024 | Kalpit Patel | B.Riley Financial | $36.00 | $18.11 | 98.79% | -39.98% |
| Apr 30, 2024 | Joel Beatty | Robert W. Baird | $36.00 | $21.30 | 69.01% | -39.98% |
| Nov 11, 2022 | Guggenheim | $16.00 | $4.60 | 247.83% | -73.32% |
The latest Longboard Pharmaceuticals stock forecast, released on Oct 14, 2024 by Kalpit Patel from B.Riley Financial, set a price target of $60.00, which represents a 2.00% increase from the stock price at the time of the forecast ($58.83), and a 0.03% increase from LBPH last price ($59.98).
Longboard Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 7 |
| Avg Price Target | - | $65.00 | $60.29 |
| Last Closing Price | $59.98 | $59.98 | $59.98 |
| Upside/Downside | -100.00% | 8.37% | 0.52% |
In the current month, the average price target of Longboard Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Longboard Pharmaceuticals's last price of $59.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Neutral | Downgrade |
| Oct 14, 2024 | Wedbush | Outperform | Neutral | Downgrade |
| Oct 14, 2024 | B. Riley | Buy | Neutral | Downgrade |
| Oct 14, 2024 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| Sep 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 05, 2024 | B. Riley | Buy | Buy | Hold |
| Jul 02, 2024 | Citigroup | Buy | Buy | Hold |
| Jul 01, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jun 11, 2024 | Citigroup | Buy | Buy | Hold |
| May 03, 2024 | Wedbush | Outperform | Outperform | Hold |
| Jan 16, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Mar 09, 2023 | Citigroup | Buy | Buy | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
Longboard Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company Downgrade its LBPH rating from "Buy" to "Neutral".
Longboard Pharmaceuticals Financial Forecast
Longboard Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | $3.00M | - |
| High Forecast | - | - | - | - | - | $3.00M | - |
| Low Forecast | - | - | - | - | - | $3.00M | - |
| # Analysts | - | - | - | - | - | 5 | - |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LBPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Longboard Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict LBPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Longboard Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Longboard Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-28.21M | $-27.50M | $-27.58M | $-26.57M | $-24.43M | $-22.54M | $-17.13M |
| High Forecast | $-28.21M | $-27.50M | $-27.58M | $-25.03M | $-23.67M | $-22.54M | $-17.13M |
| Low Forecast | $-28.21M | $-27.50M | $-27.58M | $-28.11M | $-24.81M | $-22.54M | $-17.13M |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LBPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Longboard Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Longboard Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LBPH last annual SG&A of $NaN (undefined).
Longboard Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 5 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.72 | $-0.71 | $-0.71 | $-0.68 | $-0.63 | $-0.58 | $-0.44 |
| High Forecast | $-0.72 | $-0.71 | $-0.71 | $-0.64 | $-0.61 | $-0.58 | $-0.44 |
| Low Forecast | $-0.72 | $-0.71 | $-0.71 | $-0.72 | $-0.64 | $-0.58 | $-0.44 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Longboard Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LBPH previous annual EPS of $NaN (undefined).
Longboard Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.48 | $5.50 | 1045.83% | Buy |
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |